Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study
Overview
Affiliations
Background: Large-volume total paracentesis may result in paracentesis-induced circulatory dysfunction, which is associated with poor outcomes.
Aims: To explore the short- and long-term effects of paracentesis-induced circulatory dysfunction on systemic hemodynamics, renal function and other cirrhosis-related complications in patients with refractory ascites, following subtotal large-volume paracentesis.
Methods: Patients with cirrhosis and refractory ascites without renal dysfunction had systemic hemodynamics, renal function, and neurohormones (plasma active renin, aldosterone, norepinephrine and angiotensin II) measured pre- and 6 days post-paracentesis. Paracentesis was limited to ≤8 L with 6-8 g of albumin per liter ascites drained. Patients were followed up until transjugular intrahepatic portosystemic shunt insertion, liver transplantation, or death. Paracentesis-induced circulatory dysfunction was defined as >50 % increase in plasma active renin 6 days post-paracentesis.
Results: Fifty-seven patients (mean age 59.0 ± 9.4 years) had mean 6.8 ± 1.8 L of ascites removed with 9 ± 3 g of albumin given/L of ascites drained. Patients were followed up for 715 ± 104 days. Twenty-three patients (40.4 %) developed paracentesis-induced circulatory dysfunction with unchanged serum creatinine on day six, despite worsening of hemodynamics (mean arterial pressure 90 ± 10 mmHg at baseline vs. 84 ± 8 mmHg on day six, p < 0.05). Similar hemodynamic changes were observed among patients without paracentesis-induced circulatory dysfunction. There was no significant difference in the long-term renal function or cirrhosis-related complications between the groups.
Conclusion: The occurrence of paracentesis-induced circulatory dysfunction, as defined by plasma active renin, may not have a significant short- and long-term impact on renal function or cirrhosis-related complications in patients with refractory ascites who undergo subtotal paracentesis with albumin infusion.
Drainage of ascites in cirrhosis.
Yang J, Peng Y, Zeng H, Lin X, Xu Z World J Hepatol. 2024; 16(9):1245-1257.
PMID: 39351514 PMC: 11438587. DOI: 10.4254/wjh.v16.i9.1245.
Management of refractory ascites.
Wong F Clin Mol Hepatol. 2022; 29(1):16-32.
PMID: 35676862 PMC: 9845666. DOI: 10.3350/cmh.2022.0104.
Clinical implications of prompt ascitic drain removal in cirrhosis with refractory ascites.
Wong Y, Lum H, Tan P, Teo E, Tan J, Kumar R Singapore Med J. 2021; 62(12):659-664.
PMID: 33866716 PMC: 8804429. DOI: 10.11622/smedj.2021049.
Ali B, Salim A, Alam A, Zuberi B, Ali Z, Azam Z Pak J Med Sci. 2020; 36(5):1117-1132.
PMID: 32704299 PMC: 7372671. DOI: 10.12669/pjms.36.5.2407.
Nutrition in Chronic Liver Disease.
Reddy Y, Maliakkal B, Agbim U Curr Treat Options Gastroenterol. 2019; 17(4):602-618.
PMID: 31673924 DOI: 10.1007/s11938-019-00252-3.